MedTrace Logo

Bioequivalence Study of Revolade® Eltrombopag 50 mg

NCT06834451 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-06-19

No results posted yet for this study

Summary

Bioequivalence Study

Conditions

  • Healthy
  • Healthy Donors

Interventions

DRUG

Revolade®

Tableta 50 mg Reference

DRUG

Eltrombopag (EPAG)

Tableta 50 mg

Sponsors & Collaborators

  • Centro de Atencion e Investigacion Medica

    lead NETWORK

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2025-10-30
Completion
2025-10-30

Countries

  • Colombia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06834451 on ClinicalTrials.gov